About ranibizumab
Vascular endothelial growth factor inhibitor
Used for
- Wet age-related macular degeneration
- Diabetic macular edema and diabetic retinopathy
- Macular edema after retinal vein occlusion
- Myopic choroidal neovascularization
Usual adult dose
Usually 0.5 mg injected into the eye monthly; some conditions use individualized intervals after initial doses.
Common side effects
- Eye redness, irritation, or discomfort
- Floaters or increased eye pressure
- Cataract
- Rarely, serious eye infection or retinal detachment
Important warnings
- Eye injections can rarely cause infection, bleeding, or retinal detachment.
- Rarely, treatment may increase risk of blood clots or stroke.
- Use caution with active eye infection or inflammation.
- Dose and schedule depend on the eye condition and response.
Pregnancy
Limited information; potential fetal risk is uncertain. Treatment is generally avoided during pregnancy unless clearly needed.
Breastfeeding
It is unknown whether ranibizumab passes into breast milk; discuss treatment and breastfeeding timing with a clinician.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.